WallStreetZenWallStreetZen

NASDAQ: NEUP
Neuphoria Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell NEUP stock?

Based on 1 analyst offering ratings for Neuphoria Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NEUP stock forecasts and price targets.

NEUP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-15

1 of 1

Forecast return on equity

Is NEUP forecast to generate an efficient return?

Company
N/A
Industry
25.06%
Market
177.77%

Forecast return on assets

Is NEUP forecast to generate an efficient return on assets?

Company
N/A
Industry
23.99%

NEUP earnings per share forecast

What is NEUP's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.48
Avg 2 year Forecast
-$2.51

NEUP revenue forecast

What is NEUP's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
NEUP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NEUP revenue growth forecast

How is NEUP forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
30.45%
Market
14.13%
NEUP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NEUP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NEUP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NEUP$3.30N/AN/AHold
MRKR$1.04N/AN/A
ATYR$0.17$3.50+1,911.49%Strong Buy
ESLA$0.43N/AN/A
QNTM$2.47$8.00+223.89%Strong Buy
View Top Biotech Stocks

Neuphoria Therapeutics Stock Forecast FAQ

Is Neuphoria Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NEUP) stock is to Hold NEUP stock.

Out of 1 analyst, 0 (0%) are recommending NEUP as a Strong Buy, 0 (0%) are recommending NEUP as a Buy, 1 (100%) are recommending NEUP as a Hold, 0 (0%) are recommending NEUP as a Sell, and 0 (0%) are recommending NEUP as a Strong Sell.

If you're new to stock investing, here's how to buy Neuphoria Therapeutics stock.

What is NEUP's Earnings Per Share (EPS) forecast for 2027-2028?

(NASDAQ: NEUP) Neuphoria Therapeutics's current Earnings Per Share (EPS) is -$2.18. On average, analysts forecast that NEUP's EPS will be -$2.48 for 2027, with the lowest EPS forecast at -$2.38, and the highest EPS forecast at -$2.55. In 2028, NEUP's EPS is forecast to hit -$2.51 (min: -$2.41, max: -$2.58).

What is NEUP's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: NEUP) forecast ROE is N/A, which is considered weak.

What is NEUP's earnings growth forecast for 2027-2028?

(NASDAQ: NEUP) Neuphoria Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.

Neuphoria Therapeutics's earnings in 2026 is -$9,581,147.On average, 3 Wall Street analysts forecast NEUP's earnings for 2027 to be -$13,412,532, with the lowest NEUP earnings forecast at -$12,886,551, and the highest NEUP earnings forecast at -$13,807,019.

In 2028, NEUP is forecast to generate -$13,578,119 in earnings, with the lowest earnings forecast at -$13,045,644 and the highest earnings forecast at -$13,977,476.

What is NEUP's revenue growth forecast for 2027-2029?

(NASDAQ: NEUP) Neuphoria Therapeutics's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.

Neuphoria Therapeutics's revenue in 2026 is $836,299.On average, 3 Wall Street analysts forecast NEUP's revenue for 2027 to be $0, with the lowest NEUP revenue forecast at $0, and the highest NEUP revenue forecast at $0. On average, 3 Wall Street analysts forecast NEUP's revenue for 2028 to be $0, with the lowest NEUP revenue forecast at $0, and the highest NEUP revenue forecast at $0.

In 2029, NEUP is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is NEUP's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: NEUP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.99%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.